The US Food and Drug Administration has approved Foundayo, Eli Lilly’s second GLP-1 pill for weight loss, expanding treatment options for obesity. Unlike the previously approved Wegovy pill, Foundayo offers greater convenience by allowing intake at any time of day without food or water restrictions. This new pill, which demonstrated an average weight loss of 12% in clinical trials, aims to improve access and affordability, with Lilly offering programs to reduce out-of-pocket costs for eligible patients. Foundayo joins a growing class of GLP-1 medications that mimic a hormone regulating appetite and digestion, though common gastrointestinal side effects and the need for long-term use remain considerations.
Read More
A recent UC San Diego study suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may significantly improve outcomes for colon cancer patients. Researchers analyzed data from over 6,800 patients, finding those taking GLP-1 medications had less than half the five-year mortality rate compared to those not on the drugs. This protective effect remained even after accounting for various health factors, with a more pronounced benefit in patients with high BMIs. While the exact mechanisms are still under investigation, the results point to potential anti-cancer benefits beyond the drugs’ known effects on blood sugar, inflammation, and weight.
Read More
Novo Nordisk is expanding access to its weight loss and diabetes medications, Ozempic and Wegovy, by selling them at Costco pharmacies nationwide. A one-month supply of either drug will cost $499 out of pocket for Costco members with a prescription, a move designed to compete with compounding pharmacies. While the price is the same as offered through other retailers, the expanded availability aims to improve access, despite the fact that cost and insurance coverage remain significant barriers for many, especially those with lower incomes who may benefit most from these medications. Recent research highlighting the drugs’ potential benefits for conditions like stroke and heart health further underscores the importance of wider accessibility.
Read More
Facing financial strain from competition with weight-loss drugs like Ozempic, WW International (formerly WeightWatchers) filed for Chapter 11 bankruptcy protection. This move aims to eliminate $1.15 billion in debt and restructure for future growth, allowing the company to reinvest in its members and innovate within the evolving weight management market. The reorganization is expected to be completed within 40 days, with no disruption to existing members. The company’s acquisition of telehealth provider Sequence reflects its strategic shift towards incorporating weight-loss medications into its services.
Read More
Elon Musk’s Christmas “Ozempic Santa” post revealed his use of the weight-loss drug Mounjaro, sparking further debate on GLP-1 inhibitors. This follows a recent disagreement with Robert F. Kennedy Jr., Trump’s HHS appointee, over the cost-effectiveness of widespread GLP-1 inhibitor use versus promoting healthier lifestyles to combat obesity. Musk advocates for making these drugs affordable, contrasting Kennedy’s initial focus on dietary changes. Musk’s public endorsement, however, adds another layer to the ongoing discussion surrounding obesity treatment in America.
Read More
I can’t help but feel a mix of shock and amusement when I read about the recent study linking popular weight loss and diabetes drugs to an increased risk of a rare form of blindness. The findings are certainly alarming, but as with any medical study, we must approach the results with caution and critical thinking. The study itself acknowledges that it cannot definitively prove a causal relationship between these medications and the rare eye condition known as NAION. Moreover, the small sample size and the lack of control for important factors like BMI and A1c levels raise questions about the generalizability of the results to a broader population.… Continue reading
John Q. Hosedrinker